Antibacterial vaccine against acinetobacter baumannii infection

HKU
Overview

In this invention, we conjugated pseudaminic acid which is the surface glycan of A. baumannii to a carrier protein CRM197. The resulted conjugation worked as a bacteria vaccine which could stimulate high immune responses in mice and protected the vaccinated mice from infections caused by Pseproducing A. baumannii.

  • Antibacterial vaccine against acinetobacter baumannii infection
Commercialisation opportunities
collaboration project, licensing
Problem addressed

Acinetobacter baumannii was listed as “priority pathogens" by the World Health Organization (WHO) due to its multidrug-resistance. It is lack of effective drugs for treating acinetobacter baumannii infection.

Innovation
  • Through design and synthesis of pseudaminic acid glycoconjugates, a pseudaminic acid-based vaccine against Gram-negative pathogens was developed.
Key impact
  • It is a efficient synthetic carbohydrate vaccine against gram-negative bacteria infection.
  • It is expected that Pse-based vaccines developed by this invention can be applied on other Pse-bearing Gram-negative bacteria such as Pseudomonas aeruginosa and Campylobacter jejuni.
Application
  • Acinetobacter baumannii infection
  • Pseudomonas aeruginosa infection
  • Campylobacter jejuni infection

Founded in 1911, The University of Hong Kong (HKU) is the first and oldest institution of higher education in Hong Kong. For over a century, the University has dedicated itself to creating knowledge, providing education, and serving society. Today, HKU has an established worldwide reputation for being a research-led comprehensive University with ten Faculties and a strong commitment to intellectual freedom, liberty and diversity. HKU has a proud record of academic recognition in researches through honours and awards received from both local and international bodies.

Enquiry